Canada Gazette, Part I, Volume 152, Number 10: GOVERNMENT NOTICES
March 10, 2018
DEPARTMENT OF CITIZENSHIP AND IMMIGRATION
IMMIGRATION AND REFUGEE PROTECTION ACT
Ministerial Instructions Regarding the Processing of Applications under the Federal Self-Employed Persons Class (Farm Management)
Notice is hereby given, under subsection 87.3(6) of the Immigration and Refugee Protection Act, that the Minister of Citizenship and Immigration has established the following Ministerial Instructions that, in the opinion of the Minister, will best support the attainment of the immigration goals established by the Government of Canada.
Overview
Authority for these Ministerial Instructions is derived from section 87.3 of the Immigration and Refugee Protection Act (IRPA). The Instructions are directed to officers and the Minister's delegates who are charged with handling and/or reviewing applications for permanent residence.
These Instructions come into force on the day they are published in the Canada Gazette, Part I, and apply to applications received by designated Department of Citizenship and Immigration offices on or after that date.
Any categories for which Instructions are not specifically issued shall continue to be processed in the usual manner, as per processing priorities established by the Department.
These Instructions are consistent with IRPA objectives as laid out in section 3, specifically, to pursue the maximum social, cultural and economic benefits of immigration; to enrich and strengthen the social and cultural fabric of Canadian society; to support the development of a strong and prosperous Canadian economy; to protect public health and safety and to maintain the security of Canadian society.
The Instructions are compliant with the Canadian Charter of Rights and Freedoms.
The Instructions respect all previously established accords and agreements, including the Canada-Quebec Accord on Immigration, and all existing agreements with provinces and territories.
Intake of permanent residents under the Federal Self-Employed Persons Class
Effective upon the date of publication of these Instructions in the Canada Gazette, Part I, the number of new applications that will be accepted for processing annually for Federal Self-Employed Persons Class applications where the relevant experience of the applicant is in the management of a farm under subsection 88(1) of the Immigration and Refugee Protection Regulations will be set at zero. This temporary moratorium will remain in place until otherwise indicated in a future Ministerial Instruction.
Disposition of applications
Applications for permanent residence under the Federal Self-Employed Persons Class by applicants whose relevant experience is in management of a farm that are received by designated Department of Citizenship and Immigration offices on or after the date of publication of these Instructions in the Canada Gazette, Part I, will be returned along with the processing fees.
Ottawa, February 23, 2018
Ahmed Hussen
Minister of Citizenship and Immigration
DEPARTMENT OF ENVIRONMENT
DEPARTMENT OF HEALTH
CANADIAN ENVIRONMENTAL PROTECTION ACT, 1999
Publication after screening assessment of seven hydrocarbon-based substances specified on the Domestic Substances List (paragraphs 68(b) and (c) or subsection 77(1) of the Canadian Environmental Protection Act, 1999)
Whereas spent sulphidic caustic, montan wax, and montan-wax fatty acids identified in the annex below are substances identified under subsection 73(1) of the Canadian Environmental Protection Act, 1999;
Whereas a summary of the draft screening assessment conducted on slop oil, naphtha waste, ethyne (acetylene), and montan-wax fatty acids ethylene esters pursuant to paragraphs 68(b) and (c), and on spent sulphidic caustic, montan wax, and montan-wax fatty acids pursuant to section 74 of the Act is annexed hereby;
And whereas it is proposed to conclude that the substances do not meet any of the criteria set out in section 64 of the Act,
Notice therefore is hereby given that the Minister of the Environment and the Minister of Health (the ministers) propose to take no further action on these substances at this time.
Public comment period
Any person may, within 60 days after publication of this notice, file with the Minister of the Environment written comments on the measure the ministers propose to take and on the scientific considerations on the basis of which the measure is proposed. More information regarding the scientific considerations may be obtained from the Canada.ca (Chemical Substances) website. All comments must cite the Canada Gazette, Part I, and the date of publication of this notice and be sent to the Executive Director, Program Development and Engagement Division, Department of the Environment, Gatineau, Quebec K1A 0H3, by fax to 819-938-5212, or by email to eccc.substances.eccc@canada.ca. Comments can also be submitted to the Minister of the Environment using the online reporting system available through Environment and Climate Change Canada's Single Window.
In accordance with section 313 of the Canadian Environmental Protection Act, 1999, any person who provides information in response to this notice may submit with the information a request that it be treated as confidential.
Jacqueline Gonçalves
Director General
Science and Risk Assessment Directorate
On behalf of the Minister of the Environment
David Morin
Director General
Safe Environments Directorate
On behalf of the Minister of Health
ANNEX
Summary of the draft screening assessment of seven hydrocarbon-based substances
Pursuant to section 68 or 74 of the Canadian Environmental Protection Act, 1999 (CEPA), the Minister of the Environment and the Minister of Health have conducted a screening assessment of seven hydrocarbon-based substances. Substances in this group were identified as priorities for assessment as they met categorization criteria under subsection 73(1) of CEPA or were considered a priority on the basis of other human health concerns. The Chemical Abstracts Service Registry Numbers (CAS RNfootnote 1) of these substances, their Domestic Substances List (DSL) names and their common names are listed in the table below.
| CAS RN | DSL name | Common name |
|---|---|---|
| 64742-40-1notea | Neutralizing agents (petroleum), spent sodium hydroxide | Spent sulphidic caustic |
| 68477-26-9notea,noteb | Wastes, petroleum | Slop oil |
| 68956-70-7notea,noteb | Petroleum products, C5-12, reclaimed, wastewater treatment | Naphtha waste |
| 74-86-2noteb | Ethyne | Ethyne (acetylene) |
| 8002-53-7notea | Montan wax | Montan wax |
| 68476-03-9notea | Fatty acids, montan-wax | Montan-wax fatty acids |
| 73138-45-1notea,noteb | Fatty acids, montan-wax, ethylene esters | Montan-wax fatty acids ethylene esters |
Spent sulphidic caustic, slop oil and naphtha waste are by-products or wastes generated by the petroleum industry that are recycled or reclaimed to a large extent by refineries. No information on the quantity of these petroleum refinery wastes generated in Canada was identified; however, they are all high production volume substances in the United States. Portions of these wastes that are not recycled or reclaimed or sold to industrial users are either treated and disposed of, or shipped offsite to provincial and territorial licensed waste disposal facilities, where they may be further processed. They are not used in products available to consumers and are not expected to be released to the environment. Accordingly, exposure to the environment and to the general population from these wastes or by-products is not expected and the potential risk to the environment and human health is expected to be low.
Ethyne is produced from the conversion of methane under high heat in the presence of oxygen. Ethyne is also manufactured by reacting calcium carbide and water, or may be incidentally produced as a co-product during the cracking of natural gas liquids, naphtha, or gas oil. No information on the quantity of ethyne manufactured in Canada was identified; however, it is a high production volume chemical in the United States. The primary use of ethyne is as a raw material for the production of other chemicals (e.g. 1,4-butanediol, acetylenic alcohols, ethyl and methyl vinyl ethers) in closed systems, followed by its use as a fuel for welding, cutting, and heat treating metals. Based on its use in closed industrial environments or as a fuel operating in high temperature combustion conditions, exposure to the environment and to the general population is expected to be minimal. On the basis of the minimal exposure to the environment and the general population from this substance, as well as the low estimated ecotoxicity and human toxicity of this substance, the potential risk to the environment and human health from ethyne is expected to be low.
Montan wax is a solid wax originating from lignite coal. It has similar properties and uses as the petroleum wax petrolatum, but has a non-petroleum source. In addition to crude montan wax, this assessment considers refined (bleached or deresined) montan wax and its components montan-wax fatty acids and montan-wax fatty acids ethylene esters. Refined montan wax is used in products available to consumers, including cosmetics, automotive products, household cleaning products and food packaging materials. Montan wax is expected to be released to wastewater from these uses and subsequently partition to sediments and biosolids, due to its low water solubility. Experimental and modelled toxicity data indicates that montan wax is considered to be of low ecological hazard. In addition, repeat-dose animal studies indicate low toxicity to humans. Given the low environmental and human health hazards associated with these substances, the potential risk to the environment and human health from these waxes is considered to be low.
Considering all available lines of evidence presented in this draft screening assessment, there is a low risk of harm to organisms and the broader integrity of the environment from spent sulphidic caustic, slop oil, naphtha waste, ethyne, montan wax, montan-wax fatty acids and montan-wax fatty acids ethylene esters. It is proposed to conclude that sulphidic caustic, slop oil, naphtha waste, ethyne, montan wax, montan-wax fatty acids and montan-wax fatty acids ethylene esters do not meet the criteria under paragraph 64(a) or (b) of CEPA as these substances are not entering the environment in a quantity or concentration or under conditions that have or may have an immediate or long-term harmful effect on the environment or its biological diversity or that constitute or may constitute a danger to the environment on which life depends.
On the basis of the information presented in this draft screening assessment, it is also proposed to conclude that spent sulphidic caustic, slop oil, naphtha waste, ethyne, montan wax, montan-wax fatty acids and montan-wax fatty acids ethylene esters do not meet the criteria under paragraph 64(c) of CEPA as these substances are not entering the environment in a quantity or concentration or under conditions that constitute or may constitute a danger in Canada to human life or health.
Proposed conclusion
It is proposed to conclude that spent sulphidic caustic, slop oil, naphtha waste, ethyne, montan wax, montan-wax fatty acids, and montan-wax fatty acids ethylene esters do not meet the criteria set out in section 64 of CEPA.
The draft screening assessment for these substances is available on the Canada.ca (Chemical Substances) website.
DEPARTMENT OF THE ENVIRONMENT
DEPARTMENT OF HEALTH
CANADIAN ENVIRONMENTAL PROTECTION ACT, 1999
Publication of results of investigations and recommendations for a substance — cyclohexene, 4-ethenyl- (4-vinylcyclohexene or 4-VCH), CAS RNfootnote 1 100-40-3 — specified on the Domestic Substances List (paragraphs 68(b) and (c) of the Canadian Environmental Protection Act, 1999)
Whereas a summary of the screening assessment conducted on 4-vinylcyclohexene pursuant to paragraphs 68(b) and (c) of the Act is annexed hereby;
And whereas it is concluded that the substance does not meet any of the criteria set out in section 64 of the Act,
Notice therefore is hereby given that the Minister of the Environment and the Minister of Health (the ministers) propose to take no further action on the substance at this time.
Notice is further given that the ministers will consider using information gathering mechanisms, such as those outlined in the Act, to collect information on the substance.
Catherine McKenna
Minister of the Environment
Ginette Petitpas Taylor
Minister of Health
ANNEX
Summary of the screening assessment of 4-vinylcyclohexene
Pursuant to section 68 of the Canadian Environmental Protection Act, 1999 (CEPA), the Minister of the Environment and the Minister of Health have conducted a screening assessment of cyclohexene, 4-ethenyl-, hereafter referred to as 4-vinylcyclohexene (4-VCH). The Chemical Abstracts Service Registry Number (CAS RN) for 4-VCH is 100-40-3. This substance is among those substances identified as priorities for assessment on the basis of other human health concerns.
4-VCH does not occur naturally in the environment. It is used primarily as an industrial intermediate and is chemically consumed in the manufacture of flame retardants, plastic/rubber materials and other specialty chemicals. 4-VCH may also be found as a residue in styrene-butadiene latex adhesives used in the manufacture or installation of manufactured items, such as carpets and laminated building materials. Concentrations of 4-VCH in the environment are expected to be very low due to rapid oxidation in the atmosphere and the potential for polymerization. In 2008, less than 100 kg of 4-VCH were manufactured in Canada, and between 1 000 and 10 000 kg were imported into Canada.
The ecological risk of 4-VCH was characterized using the ecological risk classification (ERC) of organic substances. The ERC is a risk-based approach that employs multiple metrics for both hazard and exposure based on weighted consideration of multiple lines of evidence for determining risk classification. Hazard profiles are established based principally on metrics regarding mode of toxic action, chemical reactivity, food web–derived internal toxicity thresholds, bioavailability, and chemical and biological activity. Metrics considered in the exposure profiles include potential emission rate, overall persistence, and long-range transport potential. A risk matrix is used to assign a low, moderate or high level of potential concern for substances based on their hazard and exposure profiles. The ERC identified 4-VCH as having a low potential to cause ecological harm.
Considering all available lines of evidence presented in this screening assessment, there is a low risk of harm to organisms and the broader integrity of the environment from 4-VCH. It is concluded that 4-VCH does not meet the criteria under paragraph 64(a) or (b) of CEPA as it is not entering the environment in a quantity or concentration or under conditions that have or may have an immediate or long-term harmful effect on the environment or its biological diversity or that constitute or may constitute a danger to the environment on which life depends.
The critical health effects for 4-VCH are carcinogenicity and reproductive toxicity as demonstrated in laboratory studies. Low toxicity was observed in short-term inhalation studies.
Exposure of the general population to 4-VCH is expected to be low. Exposure from environmental media is not expected, given that industry uses 4-VCH in closed systems. Quantities in commerce are also low. 4-VCH may be found as a residue in manufactured products containing styrene-butadiene adhesives. Available information indicates a potential for exposure as a result of off-gassing from a limited number of manufactured items containing these adhesives, but exposure would be limited, occurring only over a short period of time. Given the nature of potential exposure, risk to human health is considered to be low.
On the basis of the information presented in this screening assessment, it is concluded that 4-VCH does not meet the criteria under paragraph 64(c) of CEPA as it is not entering the environment in a quantity or concentration or under conditions that constitute or may constitute a danger in Canada to human life or health.
Overall conclusion
It is concluded that 4-VCH does not meet any of the criteria set out in section 64 of CEPA.
Consideration for follow-up
While exposure of the general population to 4-VCH is not of concern at current levels, this substance is associated with human health effects of concern. Therefore, there may be a concern for human health if exposure were to increase. Follow-up activities may involve including the substance in future information gathering initiatives, such as a mandatory survey under section 71 of CEPA.
The Government will use the data gathered through these follow-up activities to prioritize further information gathering or risk assessment of this substance, if required.
The screening assessment for this substance is available on the Canada.ca (Chemical Substances) website.
DEPARTMENT OF HEALTH
CANADIAN ENVIRONMENTAL PROTECTION ACT, 1999
Proposed guidance on the use of quantitative microbial risk assessment in drinking water
Pursuant to subsection 55(3) of the Canadian Environmental Protection Act, 1999, the Minister of Health hereby gives notice of proposed guidance on the use of quantitative microbial risk assessment in drinking water as part of the guidelines for Canadian drinking water quality. The proposed guidance document is available from March 9, 2018, to May 11, 2018, on the Consulting with Canadians website. Any person may, within 60 days after publication of this notice, file with the Minister of Health written comments on the proposed document. Comments must be sent to the Secretariat of the Federal-Provincial-Territorial Committee on Drinking Water, either by email at water_eau@hc-sc.gc.ca, or by regular mail to the Water and Air Quality Bureau, Health Canada, 269 Laurier Avenue West, A.L. 4903D, Ottawa, Ontario K1A 0K9.
March 9, 2018
David Morin
Director General
Safe Environments Directorate
On behalf of the Minister of Health
ANNEX
Executive summary
Quantitative microbiological risk assessment (QMRA) is an approach that can be used by regulatory agencies and drinking water authorities to quantify the health risks from microorganisms for water sources. It follows a common approach that includes hazard identification, exposure assessment, dose-response assessment and risk characterization. QMRA examines the entire drinking water system, from the source water to the consumer, to understand the potential impacts on public health.
Health Canada has developed and uses a QMRA model to support the development of drinking water guidelines regarding enteric viruses and protozoa. The model can also be used as part of site-specific risk assessments at drinking water treatment facilities.
Health Canada recently completed its review of the use of QMRA in drinking water. This guidance document provides an overview of the considerations, assumptions, and limitations that are necessary for conducting site-specific risk assessments. It also describes the principles, equations, and literature values used by the Health Canada QMRA model.
Assessment
QMRA can be a very useful tool in support of water safety management decisions. A well-formulated and thoughtful QMRA can offer important information on prioritizing hazards, identifying alternative risk management priorities and options, selecting appropriate interventions, conducting cost-benefit analyses of risk management actions and setting health-based performance targets. It is important to remember that QMRA does not calculate actual disease outcomes, but provides a measure of probability that disease may occur through the water system.
The intent of this document is to provide stakeholders, such as provincial and territorial regulatory authorities, decision makers, drinking water system owners, and consultants, with guidance on the use of QMRA to assist in understanding microbiological risks in Canadian water systems.
International considerations
QMRA is increasingly being applied by international agencies and governments at all levels as the foundation for informed decision-making surrounding the health risks from pathogens in drinking water. The World Health Organization, the European Commission, the Netherlands, Australia and the United States have all made important advances in QMRA validation and methodology. These agencies and governments have adopted approaches that use QMRA to inform the development of health targets and risk management regarding microbiological contaminants.
DEPARTMENT OF HEALTH
DEPARTMENT OF HEALTH ACT
Notice of annual increase of Health Canada's Drug Master Files and Certificate of a Pharmaceutical Product fees
Notice is hereby given that the Minister of Health, under the Ministerial Authority to Enter into Contract, hereby updates the fees that are payable for the provision of Drug Master Files and Certificate of a Pharmaceutical Product services by 2%, beginning April 1, 2018. These fees will continue to be updated annually, with an automatic 2% increase to align with the Drug Program's regulatory user fees.
The current fees and the fees updated as of April 1, 2018, are listed below.
Any inquiries or comments about the updated fees can be directed to Etienne Ouimette, Director General, Resource Management Operations Directorate, Health Products and Food Branch, 613-957-6690 (telephone) or cri_irc_consultations@hc-sc.gc.ca (email).
| Services | Fee as of April 1, 2017 | New Fee as of May 1, 2017 | Fee as of April 1, 2018 |
|---|---|---|---|
| Certificate of Pharmaceutical Product (or a supplemental copy of a Certificate of Pharmaceutical Product) | $86 | N/A | $88 |
| New Drug Master Files — file registration | $442 | $1,200 | $1,224 |
| Drug Master Files — letter of access | $200 | $170 | $173 |
| Drug Master Files — biannual updates | $200 | N/A | N/A |
| Drug Master Files — update | N/A | $520 | $530 |
DEPARTMENT OF HEALTH
FINANCIAL ADMINISTRATION ACT
Notice of annual increase of fees pursuant to the Fees in Respect of Drugs and Medical Devices Regulations
Notice is hereby given, under section 19.2 of the Financial Administration Act, that in keeping with section 4 of the 2011 Fees in Respect of Drugs and Medical Devices Regulations, every fee outlined by the Regulations is to be increased annually by 2%, rounded up to the nearest dollar.
The current fees and the fees updated as of April 1, 2018, are listed below.
Any inquiries or comments about the updated fees can be directed to Etienne Ouimette, Director General, Resource Management Operations Directorate, Health Products and Food Branch, 613-957-6690 (telephone) or cri_irc_consultations@hc-sc.gc.ca (email).
| Fee Category | Section in Fees in Respect of Drugs and Medical Devices Regulations | Fee as of April 1, 2017 | Fee as of April 1, 2018 |
|---|---|---|---|
| PART 2 — DRUGS Fees for Examination Services — Schedule 1 |
|||
| New active substance | 6 | $341,770 | $348,606 |
| Clinical or non-clinical data and chemistry and manufacturing data | 6 | $173,106 | $176,569 |
| Clinical or non-clinical data only | 6 | $80,794 | $82,410 |
| Comparative studies | 6 | $48,834 | $49,811 |
| Chemistry and manufacturing data only | 6 | $23,089 | $23,551 |
| Published data only | 6 | $19,147 | $19,530 |
| Switch from prescription to non-prescription status | 6 | $46,491 | $47,421 |
| Labelling only | 6 | $3,111 | $3,174 |
| Administrative submission | 6 | $324 | $331 |
| Disinfectants | 6 | $4,305 | $4,392 |
| Drug identification number application —labelling standards | 6 | $1,726 | $1,761 |
| Remission | |||
| Remission processing fee | 11(1)(a)(iii) | $566 | $578 |
| Establishment Licence Fees Fabrication of Drugs — Schedule 2 |
|||
| Basic fee | 19(1), 27, 28(1)(a), 28(2)(a) | $17,402 | $17,751 |
| Each additional category | 19(1)(a) | $4,361 | $4,449 |
| Dosage form classes: | $0 | $0 | |
| 2 classes | 19(1)(b) | $8,708 | $8,883 |
| 3 classes | 19(1)(b) | $17,402 | $17,751 |
| 4 classes | 19(1)(b) | $21,762 | $22,198 |
| 5 classes | 19(1)(b) | $26,106 | $26,629 |
| 6 classes | 19(1)(b) | $30,454 | $31,064 |
| Each additional class | 19(1)(b) | $1,748 | $1,783 |
| Sterile dosage forms | 19(1)(c) | $8,708 | $8,883 |
| Packaging/Labelling of Drugs — Schedule 3 | |||
| Basic fee | 20(1), 20(3)(a), 28(1)(b), 28(2)(b) | $11,636 | $11,869 |
| Each additional category | 20(1)(a) | $2,907 | $2,966 |
| Dosage form classes: | $0 | $0 | |
| 2 classes | 20(1)(b) | $5,803 | $5,920 |
| 3 or more classes | 20(1)(b) | $8,708 | $8,883 |
| Importation and Distribution of Drugs — Schedule 4 | |||
| Basic fee | 21(a), 22, 28(1)(c) and (d), 28(2)(c) and (d) | $7,256 | $7,402 |
| Each additional category | 21(a)(i), 22(a) | $1,816 | $1,853 |
| Dosage form classes: | $0 | $0 | |
| 2 classes | 21(a)(ii), 22(b) | $3,630 | $3,703 |
| 3 or more classes | 21(a)(ii), 22(b) | $7,256 | $7,402 |
| Each fabricator | 21(b)(i) | $1,748 | $1,783 |
| Each additional dosage form class for each fabricator | 21(b)(ii) | $881 | $899 |
| Distribution or Wholesaling | |||
| Distribution or wholesaling fee | 23 | $4,361 | $4,449 |
| Testing | |||
| Testing fee | 24 | $2,907 | $2,966 |
| Drug Analysis — Schedule 5 | |||
| Vaccines (1) | 25 | $29,001 | $29,582 |
| Drugs, not included in items 1, 6 and 9 of this Schedule, that are listed in Schedule D to the Food and Drugs Act | 25 | $11,603 | $11,836 |
| Drugs for human use that are listed in Schedule F to the Food and Drug Regulations that are controlled drugs or narcotics | 25 | $8,708 | $8,883 |
| Drugs for human use, not included in any other item, for which a drug identification number has been assigned | 25 | $4,361 | $4,449 |
| Radiopharmaceuticals | 25 | $0 | $0 |
| Whole blood and its components (6) | 25 | $0 | $0 |
| Hemodialysis products | 25 | $0 | $0 |
| Drugs that are labelled as disinfectants, including those listed in paragraph 9(f) of this Schedule, but excluding other drugs labelled as disinfectants of medical devices | 25 | $0 | $0 |
| Drugs that meet the requirements of a class monograph having one of the following titles (9): | $0 | $0 | |
| Acne Therapies | 25 | $0 | $0 |
| Antidandruff Products | 25 | $0 | $0 |
| Antiperspirants | 25 | $0 | $0 |
| Antiseptic Skin Cleaners | 25 | $0 | $0 |
| Athlete's Foot Treatments | 25 | $0 | $0 |
| Contact Lens Disinfectants 9(f) | 25 | $0 | $0 |
| Fluoride-Containing Anti-Caries Products | 25 | $0 | $0 |
| Medicated Skin Care Products | 25 | $0 | $0 |
| Sunburn Protectants | 25 | $0 | $0 |
| Throat Lozenges | 25 | $0 | $0 |
| Fees for the Examination of Dealer's Licence Applications Dealer's Licence |
|||
| Dealer's licence | 31(1) | $5,082 | $5,184 |
| Fees for Right to Sell Drugs | |||
| Annual fee | 35(1) | $1,152 | $1,176 |
| PART 3 — MEDICAL DEVICE FEES Fees for the Examination of Medical Device Licence Applications Class II Medical Devices |
|||
| Class II — Licence application | 39(1) | $397 | $405 |
| Class III Medical Devices — Schedule 6 | |||
| Licence application | 40(1)(a), 41(a) | $5,691 | $5,805 |
| Licence application for a near patient in vitro diagnostic devices | 40(1)(a), 41(a) | $9,687 | $9,881 |
| Change referred to in paragraph 34(a) of the Medical Devices Regulations that relates to manufacturing | 40(1)(a), 41(a) | $1,433 | $1,462 |
| Any other change referred to in paragraph 34(a) or (b) of the Medical Devices Regulations | 40(1)(a), 41(a) | $5,330 | $5,437 |
| Class IV Medical Devices — Schedule 7 | |||
| Licence application | 40(1)(b), 41(b) | $13,235 | $13,500 |
| Licence application for devices that contain human or animal tissue | 40(1)(b), 41(b) | $12,347 | $12,594 |
| Licence application for near patient in vitro diagnostic device | 40(1)(b), 41(b) | $22,560 | $23,012 |
| Change referred to in paragraph 34(a) of the Medical Devices Regulations that relates to manufacturing | 40(1)(b), 41(b) | $1,433 | $1,462 |
| Any other change referred to in paragraph 34(a) or (b) of the Medical Devices Regulations | 40(1)(b), 41(b) | $6,073 | $6,195 |
| Remission | |||
| Remission processing fee | 44(1)(a)(iii) | $61 | $63 |
| Fee for Right to Sell Licensed Class II, III or IV Medical Devices | |||
| Fee (if annual gross revenue medical device sales is less than $20,000) | 48(1)(a) | $61 | $63 |
| Fee (in any other case) | 48(1)(b) | $375 | $383 |
| Fees for the Examination of an Application for an Establishment Licence | |||
| Medical devices establishment licence | 51(1) | $8,109 | $8,272 |
DEPARTMENT OF HEALTH
PATENT ACT
Notice of annual increase of fees pursuant to the Certificate of Supplementary Protection Regulations
Notice is hereby given that, in keeping with subsection 9(1) of the Certificate of Supplementary Protection Regulations, the fee has increased, and will increase, by the annual 2% amount, rounded up to the nearest dollar. These changes will apply to applications filed after September 21, 2017, and April 1, 2018.
The current fee and the fee updated as of April 1, 2018, are listed below.
Any inquiries or comments about the updated fees can be directed to Etienne Ouimette, Director General, Resource Management Operations Directorate, Health Products and Food Branch, 613-957-6690 (telephone) or cri_irc_consultations@hc-sc.gc.ca (email).
| - | Subsection in the Certificate of Supplementary Protection Regulations | New Fee as of September 21, 2017 | Fee as of April 1, 2018 |
|---|---|---|---|
| Certificate of supplementary protection | 9(1) | $9,011 | $9,192 |
DEPARTMENT OF HEALTH
HAZARDOUS MATERIALS INFORMATION REVIEW ACT
Filing of claims for exemption
Pursuant to paragraph 12(1)(a) of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of the filing of the claims for exemption listed below.
In accordance with subsection 12(2) of the Hazardous Materials Information Review Act, affected parties, as defined, may make written representations to the screening officer with respect to the claim for exemption and the safety data sheet (SDS) or label to which it relates. Written representations must cite the appropriate registry number, state the reasons and evidence upon which the representations are based and be delivered within 30 days of the date of the publication of this notice in the Canada Gazette, Part I, to the screening officer at the following address: Workplace Hazardous Materials Bureau, 269 Laurier Avenue West, 8th Floor, Ottawa, Ontario K1A 0K9.
Julie Calendino
Chief Screening Officer
On February 11, 2015, the Hazardous Products Act (HPA) was amended and the Controlled Products Regulations (CPR) and the Ingredient Disclosure List were repealed and replaced with the new Hazardous Products Regulations (HPR). The revised legislation (HPA/HPR) is referred to as WHMIS 2015 and the former legislation (HPA/CPR) is referred to as WHMIS 1988. Transitional provisions allow compliance with either WHMIS 1988 or WHMIS 2015 for a specified period of time.
The claims listed below seek an exemption from the disclosure of supplier confidential business information in respect of a hazardous product; such disclosure would otherwise be required under the provisions of the relevant legislation.
| Claimant | Product Identifier | Subject of the Claim for Exemption | Registry Number |
|---|---|---|---|
| Canadian Energy Services | PCSURF-3511 | C.i. and C. of one ingredient | 11885 |
| Momentive Performance Materials | Niax* catalyst EF-708 | C.i. and C. of two ingredients C. of two ingredients | 11886 |
| Nalco Canada ULC | NALCO® EC1652A | C.i. and C. of two ingredients C. of two ingredients | 11887 |
| Flotek Chemistry | StimOil PD 126 | C.i. and C. of two ingredients C. of three ingredients | 11888 |
| Canadian Energy Services | WRXSOL Poly CI-A | C.i. and C. of one ingredient | 11889 |
| Nalco Canada ULC | CORR11540W | C.i. and C. of three ingredients C. of four ingredients | 11890 |
| Canadian Energy Services | WRXSOL Poly CI-B | C.i. and C. of two ingredients | 11891 |
| Covestro LLC | BAYFILL 56IF05U | C.i. of two ingredients C. of four ingredients | 11892 |
| The Lubrizol Corporation | Lubrizol ® 5060 | C.i. and C. of two ingredients | 11893 |
| The Lubrizol Corporation | ADDCO TM 402-G | C.i. and C. of one ingredient | 11894 |
| LIFELAST | DuraShield 310 Resin | C. of eight ingredients C.i. of two ingredients | 11895 |
| BP Lubricants | Molub-Alloy OG 936 SF Heavy Spray | C. of eight ingredients | 11896 |
| BP Lubricants | Rustilo Aqua 21 | C. of five ingredients | 11897 |
| BP Lubricants | Optigear Synthetic X 320 AD | C. of one ingredient | 11898 |
| BP Lubricants | Alpha HC 320 EP | C. of three ingredients | 11899 |
| BP Lubricants | Alpha HC 320 | C. of one ingredient | 11900 |
| BP Lubricants | Hysol SL 35 XBB | C. of seven ingredients | 11901 |
| BP Lubricants | Alusol SL 51 XBB | C. of seven ingredients | 11902 |
| Americhem Clay Stabilizer, LLC | ACS ClayLOK | C.i. and C. of three ingredients | 11903 |
| Multi-Chem Production Chemicals Co. | MC MXI 3-2831 | C.i. of two ingredients | 11904 |
| Multi-Chem Production Chemicals Co. | MC MX 924A-5 | C.i. of two ingredients | 11905 |
| Calfrac Well Services Ltd. | DynaRate 6524 | C.i. of three ingredients | 11906 |
| Halliburton Group Canada | D-AIR 3000W | C.i. of one ingredient C. of two ingredients | 11907 |
| Halliburton Group Canada | HAI-404M | C.i. of six ingredients C. of ten ingredients | 11908 |
| Halliburton Group Canada | LCA-1 | C.i. of one ingredient C. of one ingredient | 11909 |
| Nalco Canada ULC | FROTH PRO 706 | C.i. and C. of one ingredient | 11910 |
| Covestro LLC | Bayhydur 303 | C.i. of one ingredient C. of three ingredients | 11911 |
| Covestro LLC | BAYTHERM 871 COMPONENT B | C.i. of one ingredient C. of five ingredients | 11912 |
| Covestro LLC | BAYDUR 684 COMP B | C.i. and C. of three ingredients | 11913 |
| Baker Hughes Canada Company | PETROSWEET™ HSO3510A SCAVENGER | C.i. and C. of one ingredient C. of eight ingredients | 11914 |
| Imperial Oil Limited | Mobil Rarus 829 | C. of four ingredients | 11915 |
| Imperial Oil Limited | CAT EXTREME APPLICATION GREASE 1 | C. of nine ingredients | 11917 |
| Suez Water Technologies & Solutions Canada | PROSWEET S1800 | C.i. and C. of one ingredient | 11918 |
| Calfrac Well Services Ltd. | DynaRate 6106 | C.i. and C. of one ingredient C. of two ingredients | 11919 |
| Baker Hughes Canada Company | BPR 44855R SETTLING AID | C. of four ingredients C.i. of one ingredient | 11920 |
| Covestro LLC | BAYFILL 53IF33 | C.i. and C. of one ingredient | 11921 |
| Nalco Canada ULC | NALCO® 63431 | C.i. and C. of one ingredient | 11922 |
| Schlumberger Canada Limited | WT-1040 | C. of one ingredient | 11923 |
| Schlumberger Canada Limited | CAL-ACID* 2020 | C. of two ingredients | 11924 |
| Afton Chemical Corporation | HiTEC 6406C Fuel Additive | C.i. and C. of two ingredients | 11925 |
| Baker Hughes Canada Company | HI-M-PACT™ 5557 KHI Hydrate Inhibitor | C.i. of one ingredient C. of four ingredients | 11926 |
- Note: C.i. = chemical identity and C. = concentration
DEPARTMENT OF INDUSTRY
OFFICE OF THE REGISTRAR GENERAL
| Name and position | Order in Council |
|---|---|
| Burns, Marta E. | 2018-174 |
Court of Queen's Bench of Alberta |
- |
Justice |
- |
Court of Appeal of Alberta |
- |
Judge ex officio |
- |
| Federal Court | - |
Judges |
- |
| Federal Court of Appea | - |
Judges ex officio |
- |
Norris, John |
2018-185 |
Walker, Elizabeth |
2018-184 |
| Her Majesty's Court of Queen's Bench for Saskatchewan | - |
Judges/Juges |
- |
MacMillan-Brown, Heather D., Q.C. |
2018-175 |
McCreary, Meghan, Q.C. |
2018-176 |
| Leef, Karen D. M. | 2018-177 |
Superior Court of Justice in and for the Province of Ontario, a member of the Family Court branch |
- |
Judge |
- |
Court of Appeal for Ontario |
- |
Judge ex officio |
- |
| Paquet, Sarah | 2018-179 |
Shared Services Canada |
- |
Executive Vice-president |
- |
| Semaan, Nada | 2018-178 |
Financial Transactions and Reports Analysis Centre of Canada |
- |
Director |
- |
| Supreme Court of British Columbia | - |
Judges |
- |
Baker, Wendy A., Q.C. |
2018-172 |
Matthews, Sharon, Q.C. |
2018-173 |
Norell, Barbara J., Q.C. |
2018-171 |
| Wallace, Peter | 2018-145 |
Secretary of the Treasury Board |
- |
March 1, 2018
Diane Bélanger
Official Documents Registrar
DEPARTMENT OF TRANSPORT
CANADA SHIPPING ACT, 2001
Western Canada Marine Response Corporation
Notice of an addition to the fees charged by Western Canada Marine Response Corporation pursuant to an arrangement required by subsection 168(1) of the Canada Shipping Act, 2001
Description
Western Canada Marine Response Corporation ("WCMRC") is a certified response organization pursuant to section 169 of the Act in respect of a rated capability of 10 000 tonnes and a geographic area covering the waters bordering British Columbia (including the shorelines associated with such waters) and excluding waters north of 60° north latitude. This notice establishes an additional bulk oil cargo fee for the Trans Mountain Expansion Project, to be charged in addition to the registration and bulk oil cargo fees, and any amendments thereto, as published by notice in the Canada Gazette, Part I.
Definitions
- 1. In this notice of fees,
- "Act" means the Canada Shipping Act, 2001. (Loi)
- "BOCF" means the bulk oil cargo fee payable to WCMRC in relation to an arrangement required by subsections 167(1) and 168(1) of the Act, and any amendments thereto, as published by notice in the Canada Gazette, Part I. [droits sur les produits pétroliers en vrac (DPPV)]
- "registration fees" means the registration fees payable to WCMRC in relation to an arrangement required by subsections 167(1) and 168(1) of the Act, and any amendments thereto, as published by notice in the Canada Gazette, Part I. (droits d'enregistrement)
- "TMEP BOCF" means the Trans Mountain Expansion Project bulk oil cargo fee, a fee charged on crude oil shipments in bulk loaded onto a ship (bulk oil) and intended for international destinations and destinations north of 60° north latitude, except shipments of jet fuel, from the Westridge oil handling facility owned by Trans Mountain Pipeline L.P. [droits sur les produits pétroliers en vrac du projet d'expansion de Trans Mountain (DPPV PETM)]
Trans Mountain Expansion Project bulk oil cargo fee
- 2. In relation to the arrangement with WCMRC for the Westridge oil handling facility, the TMEP BOCF will be determined by multiplying the total number of tonnes of oil loaded, within the meaning of the TMEP BOCF definition, by the TMEP BOCF rate per tonne of bulk oil.
- 3. The TMEP BOCF rate applicable is five dollars and sixty-nine and five-tenth cents ($5.695) per tonne of bulk oil, plus all applicable taxes, from April 1, 2018.
- 4. The TMEP BOCF will be charged in addition to the registration fees and BOCF, as amended from time to time, as published by notice in the Canada Gazette, Part I.
Interested persons may, within 30 days after the date of publication of this notice, file notices of objection that contain the reasons for the objection to the Manager, Marine Safety and Security, Transport Canada, Place de Ville, Tower C, 10th Floor, 330 Sparks Street, Ottawa, Ontario K1A 0N8, 613-993-8196 (fax), marinesafety-securitemaritime@tc.gc.ca (email). All such representations must cite the Canada Gazette, Part I, the name of the response organization submitting the list of proposed amended fees, and the date of publication of the notice of proposed amended fees.
February 28, 2018
Mark Johncox, CA
PRIVY COUNCIL OFFICE
Appointment opportunities
We know that our country is stronger — and our government more effective — when decision-makers reflect Canada's diversity. The Government of Canada has implemented an appointment process that is transparent and merit-based, strives for gender parity, and ensures that Indigenous peoples and minority groups are properly represented in positions of leadership. We will continue to search for Canadians who reflect the values that we all embrace: inclusion, honesty, fiscal prudence, and generosity of spirit. Together, we will build a government as diverse as Canada.
The Government of Canada is currently seeking applications from diverse and talented Canadians from across the country who are interested in the following positions.
Current opportunities
The following opportunities for appointments to Governor in Council positions are currently open for applications. Every opportunity is open for a minimum of two weeks from the date of posting on the Governor in Council Appointments website.
| Position | Organization | Closing date |
|---|---|---|
| President and Chief Executive Officer | Canada Infrastructure Bank | - |
| Chairperson | Canada Lands Company Limited | - |
| President and Chief Executive Officer | Canada Post Corporation | - |
| Chief Executive Officer | Canadian Air Transport Security Authority | - |
| President | Canadian Broadcasting Corporation | - |
| Chief Executive Officer | Canadian Dairy Commission | - |
| President | Canadian Nuclear Safety Commission | - |
| Chairperson and Members | Canadian Transportation Accident Investigation and Safety Board | March 19, 2018 |
| Commissioner of Corrections | Correctional Service Canada | - |
| Director | First Nations Financial Management Board | March 12, 2018 |
| Members (appointment to roster) | International Trade and International Investment Dispute Settlement Bodies | - |
| Parliamentary Librarian | Library of Parliament | - |
| Director (Federal Representative) | Nanaimo Port Authority | March 12, 2018 |
| Chief Electoral Officer | Office of the Chief Electoral Officer | - |
| Information Commissioner | Office of the Information Commissioner | - |
| Director (Federal Representative) | Port Alberni Port Authority | March 12, 2018 |
| Commissioner | Royal Canadian Mounted Police | - |
| Chairperson | Social Security Tribunal | - |
| Vice-Chair and Members | Standards Council of Canada | March 26, 2018 |
| Executive Director | Telefilm Canada | - |
| Chief Executive Officer | Windsor-Detroit Bridge Authority | - |
Ongoing opportunities
| Position | Organization | Closing date |
|---|---|---|
| Full-time and Part-time Members | Immigration and Refugee Board | June 29, 2018 |
| Members | Parole Board of Canada | - |
Upcoming opportunities
| Position | Organization |
|---|---|
| Chairperson | Civilian Review and Complaints Commission for the Royal Canadian Mounted Police |
| Sergeant-at-Arms | House of Commons |
| Commissioner | International Joint Commission |